Literature DB >> 1688807

Hemopoietic effects of short-term in vivo treatment of mice with various doses of rhG-CSF.

Z Pojda1, G Molineux, T M Dexter.   

Abstract

Recombinant human granulocyte colony-stimulating factor (rhG-CSF) was injected s.c., twice daily, into normal adult male BDF1 mice for a period of 4-5 days in doses ranging from 10 to 2500 micrograms/kg/day. The number of peripheral blood cells and their morphology was examined daily from the beginning of the experiment for 6 days. On the 5th day of treatment parameters such as spleen weight and cellularity, bone marrow morphology and cellularity, content of granulocyte-macrophage colony-forming cells (GM-CFC) or multipotential stem cells (CFU-S) in spleen and marrow, and also histology of lung and liver were examined. We observed a dose-dependent increase in the number of blood neutrophils, and an increase in weight, cellularity, and numbers of GM-CFC and CFU-S in the spleen. In the bone marrow, cellularity decreased to 40% of normal. Numbers of GM-CFC and CFU-S in marrow were also decreased, and examination of marrow morphology revealed an inhibition of erythropoiesis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688807

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  7 in total

Review 1.  G-CSF: status quo and new indications.

Authors:  F Herrmann
Journal:  Infection       Date:  1992 Jul-Aug       Impact factor: 3.553

2.  MPXI and early neutrophilia: new potential therapeutic biomarkers for recombinant human granulocyte colony-stimulating factor.

Authors:  N Charuruks; N Voravud; V Sriuranpong
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

Review 3.  Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions.

Authors:  L M Hollingshead; K L Goa
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

4.  Effect of stem cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor on morphology of haematopoietic organs in mice.

Authors:  P Szumilas; K Barcew; M Baśkiewicz-Masiuk; B Wiszniewska; M Z Ratajczak; B Machaliński
Journal:  Cell Prolif       Date:  2005-02       Impact factor: 6.831

5.  G-CSF partially mediates effects of sleeve gastrectomy on the bone marrow niche.

Authors:  Ziru Li; Julie Hardij; Simon S Evers; Chelsea R Hutch; Sarah M Choi; Yikai Shao; Brian S Learman; Kenneth T Lewis; Rebecca L Schill; Hiroyuki Mori; Devika P Bagchi; Steven M Romanelli; Ki-Suk Kim; Emily Bowers; Cameron Griffin; Randy J Seeley; Kanakadurga Singer; Darleen A Sandoval; Clifford J Rosen; Ormond A MacDougald
Journal:  J Clin Invest       Date:  2019-05-06       Impact factor: 14.808

6.  Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice.

Authors:  T Lazard; C Perronne; Y Cohen; J Grosset; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

7.  G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses.

Authors:  Mark P Rubinstein; Mohamed L Salem; Andrew L Doedens; Caitlin J Moore; Cody Chiuzan; Guillermo L Rivell; David J Cole; Ananda W Goldrath
Journal:  J Hematol Oncol       Date:  2013-10-01       Impact factor: 17.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.